Search
forLearn
5 / 801 resultslearn oligopeptide-71
learn HT-B
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn LHA™
Research
5 / 426 results
research Molecular functional analyses revealed essential roles of HSP90 and lamin A/C in growth, migration, and self-aggregation of dermal papilla cells
HSP90 and lamin A/C are crucial for hair growth and could be targets for treating hair loss.
research HSP90 Inhibition and Cellular Stress Elicits Phenotypic Plasticity in Hematopoietic Differentiation
Inhibiting HSP90 increases cell adaptability and survival under stress.
research LSD1 interacting with HSP90 promotes skin wound healing by inducing metabolic reprogramming of hair follicle stem cells through the c‐MYC/LDHA axis
LSD1 and HSP90 help heal skin wounds by changing hair follicle stem cells' metabolism.
research Therapeutic effect of mesenchymal stem cells on histopathological, immunohistochemical, and molecular analysis in second-grade burn model
Bone marrow-derived stem cells improved healing and reduced scarring in second-degree burns in rats.
research N-terminal functional domain of Gasdermin A3 regulates mitochondrial homeostasis via mitochondrial targeting
Mutations in Gasdermin A3 cause skin inflammation and hair loss by disrupting mitochondria.
Community Join
5 / 1000+ resultscommunity (Topical) Quercetin might be a good add on to the hair loss stack
Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.
community Isn't it kind of strange that hair loss happens at where the 2 main superficial temporal arterty branches (temples and crown) are?
Hair loss may be linked to blood flow and inflammation, with treatments like Minoxidil, finasteride, and quercetin being discussed. The conversation also mentions the role of 5AR enzyme distribution in hair follicles.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community Hope Medicine's HMI-115 could be out in 2027 per Company Founder
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.